ImmunoGen, Inc. Quarterly Common Stock, Shares Authorized from Q2 2011 to Q3 2023

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
ImmunoGen, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q2 2011 to Q3 2023.
  • ImmunoGen, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2023 was 600M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 600M 0 0% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 600M 0 0% Jun 30, 2023 10-Q 2023-07-31
Q1 2023 600M +300M +100% Mar 31, 2023 10-Q 2023-04-28
Q4 2022 600M 0 0% Dec 31, 2022 10-Q 2023-11-02
Q3 2022 600M +300M +100% Sep 30, 2022 10-Q 2022-11-04
Q2 2022 600M +300M +100% Jun 30, 2022 10-Q 2022-08-01
Q1 2022 300M 0 0% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 600M +300M +100% Dec 31, 2021 10-K 2023-03-01
Q3 2021 300M 0 0% Sep 30, 2021 10-Q 2021-10-29
Q2 2021 300M 0 0% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 300M +100M +50% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 300M +100M +50% Dec 31, 2020 10-K 2022-02-28
Q3 2020 300M +100M +50% Sep 30, 2020 10-Q 2020-11-06
Q2 2020 300M +100M +50% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 200M 0 0% Mar 31, 2020 10-Q 2020-05-05
Q4 2019 200M 0 0% Dec 31, 2019 10-K 2021-03-01
Q3 2019 200M +200M +99900% Sep 30, 2019 10-Q 2019-11-05
Q2 2019 200M +200M +99900% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 200M 0 0% Mar 31, 2019 10-Q 2019-05-07
Q4 2018 200M 0 0% Dec 31, 2018 10-K 2020-03-11
Q3 2018 200K* -200M -99.9% Sep 30, 2018 10-Q 2018-11-02
Q2 2018 200K* -150M -99.9% Jun 30, 2018 10-Q 2018-08-03
Q1 2018 200M +50M +33.3% Mar 31, 2018 10-Q 2018-05-09
Q4 2017 200M 0 0% Dec 31, 2017 10-K 2019-03-01
Q3 2017 200M +50M +33.3% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 150M 0 0% Jun 30, 2017 10-Q 2017-08-04
Q1 2017 150M 0 0% Mar 31, 2017 10-Q 2017-05-05
Q4 2016 200M +50M +33.3% Dec 31, 2016 10-K 2018-03-07
Q3 2016 150M 0 0% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 150M 0 0% Jun 30, 2016 10-KT 2017-03-03
Q1 2016 150M 0 0% Mar 31, 2016 10-Q 2016-05-04
Q4 2015 150M 0 0% Dec 31, 2015 10-Q 2016-02-04
Q3 2015 150M 0 0% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 150M 0 0% Jun 30, 2015 10-KT 2017-03-03
Q1 2015 150M 0 0% Mar 31, 2015 10-Q 2015-05-08
Q4 2014 150M 0 0% Dec 31, 2014 10-Q 2015-02-05
Q3 2014 150M 0 0% Sep 30, 2014 10-Q 2014-10-30
Q2 2014 150M 0 0% Jun 30, 2014 10-K 2015-08-27
Q1 2014 150M 0 0% Mar 31, 2014 10-Q 2014-05-02
Q4 2013 150M 0 0% Dec 31, 2013 10-Q 2014-02-05
Q3 2013 150M +50M +50% Sep 30, 2013 10-Q 2013-10-29
Q2 2013 150M 0 0% Jun 30, 2013 10-K 2014-08-28
Q1 2013 150M +50M +50% Mar 31, 2013 10-Q 2013-05-06
Q4 2012 150M +50M +50% Dec 31, 2012 10-Q 2013-01-30
Q3 2012 100M 0 0% Sep 30, 2012 10-Q 2012-10-31
Q2 2012 150M +50M +50% Jun 30, 2012 10-K 2013-08-29
Q1 2012 100M Mar 31, 2012 10-Q 2012-05-10
Q4 2011 100M Dec 31, 2011 10-Q 2012-01-31
Q3 2011 100M Sep 30, 2011 10-Q 2011-10-31
Q2 2011 100M Jun 30, 2011 10-K 2012-08-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.